PortalPublikationenA Gradient of Intestinal Inflammation in Primary Sclerosing ...

A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis

Standard

A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis. / Wittek, Agnes; Steglich, Babett; Casar, Christian; Seiz, Oliver; Huber, Philipp; Ehlken, Hanno; Reher, Dominik; Wende, Sandra; Bedke, Tanja; Kempski, Jan; Böttcher, Marius; Bang, Corinna; Thingholm, Louise; Krech, Till; Lohse, Ansgar W; Sauter, Guido; Rösch, Thomas; Franke, Andre; Schramm, Christoph; Gagliani, Nicola; Pelczar, Penelope; Huber, Samuel.

in: INFLAMM BOWEL DIS, Jahrgang 30, Nr. 6, 03.06.2024, S. 900-910.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wittek, A, Steglich, B, Casar, C, Seiz, O, Huber, P, Ehlken, H, Reher, D, Wende, S, Bedke, T, Kempski, J, Böttcher, M, Bang, C, Thingholm, L, Krech, T, Lohse, AW, Sauter, G, Rösch, T, Franke, A, Schramm, C, Gagliani, N, Pelczar, P & Huber, S 2024, 'A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis', INFLAMM BOWEL DIS, Jg. 30, Nr. 6, S. 900-910. https://doi.org/10.1093/ibd/izad137

APA

Wittek, A., Steglich, B., Casar, C., Seiz, O., Huber, P., Ehlken, H., Reher, D., Wende, S., Bedke, T., Kempski, J., Böttcher, M., Bang, C., Thingholm, L., Krech, T., Lohse, A. W., Sauter, G., Rösch, T., Franke, A., Schramm, C., ... Huber, S. (2024). A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis. INFLAMM BOWEL DIS, 30(6), 900-910. https://doi.org/10.1093/ibd/izad137

Vancouver

Wittek A, Steglich B, Casar C, Seiz O, Huber P, Ehlken H et al. A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis. INFLAMM BOWEL DIS. 2024 Jun 3;30(6):900-910. https://doi.org/10.1093/ibd/izad137

Bibtex

@article{a6902d49211947eda537dd6f62f8e5c7,
title = "A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis",
abstract = "BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive liver disease associated with inflammatory bowel disease (IBD). The percentage of PSC patients diagnosed with concomitant IBD varies considerably between studies. This raises the question whether all PSC patients would show intestinal inflammation if screened thoroughly, even in the absence of symptoms.METHODS: To address this question, we collected intestinal biopsies of healthy controls (n = 34), PSC (n = 25), PSC-IBD (n = 41), and IBD (n = 51) patients in a cross-sectional study and carried out cytokine expression profiling, 16S sequencing, in-depth histology, and endoscopy scoring.RESULTS: We found that the vast majority of PSC patients even without clinically manifest IBD showed infiltration of immune cells and increased expression of IL17A and IFNG in intestinal biopsies. However, expression of IL10 and FOXP3 were likewise increased, which may explain why these PSC patients have intestinal inflammation only on a molecular level. This subclinical inflammation in PSC patients was focused in the distal colon, whereas PSC-IBD patients showed inflammation either at the distal colon or on the right side of the colon and the terminal ileum. Furthermore, we observed that PSC patients without IBD showed signs of dysbiosis and exhibited a distinct microbial profile compared with healthy controls.CONCLUSIONS: We found a gradient of intestinal inflammation in the vast majority of PSC patients even in the absence of IBD. Thus, further studies evaluating the effect of anti-inflammatory therapies in PSC patients and their impact on the emergence of clinically manifest IBD and colorectal cancer development are needed.",
author = "Agnes Wittek and Babett Steglich and Christian Casar and Oliver Seiz and Philipp Huber and Hanno Ehlken and Dominik Reher and Sandra Wende and Tanja Bedke and Jan Kempski and Marius B{\"o}ttcher and Corinna Bang and Louise Thingholm and Till Krech and Lohse, {Ansgar W} and Guido Sauter and Thomas R{\"o}sch and Andre Franke and Christoph Schramm and Nicola Gagliani and Penelope Pelczar and Samuel Huber",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Crohn{\textquoteright}s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2024",
month = jun,
day = "3",
doi = "10.1093/ibd/izad137",
language = "English",
volume = "30",
pages = "900--910",
journal = "INFLAMM BOWEL DIS",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis

AU - Wittek, Agnes

AU - Steglich, Babett

AU - Casar, Christian

AU - Seiz, Oliver

AU - Huber, Philipp

AU - Ehlken, Hanno

AU - Reher, Dominik

AU - Wende, Sandra

AU - Bedke, Tanja

AU - Kempski, Jan

AU - Böttcher, Marius

AU - Bang, Corinna

AU - Thingholm, Louise

AU - Krech, Till

AU - Lohse, Ansgar W

AU - Sauter, Guido

AU - Rösch, Thomas

AU - Franke, Andre

AU - Schramm, Christoph

AU - Gagliani, Nicola

AU - Pelczar, Penelope

AU - Huber, Samuel

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2024/6/3

Y1 - 2024/6/3

N2 - BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive liver disease associated with inflammatory bowel disease (IBD). The percentage of PSC patients diagnosed with concomitant IBD varies considerably between studies. This raises the question whether all PSC patients would show intestinal inflammation if screened thoroughly, even in the absence of symptoms.METHODS: To address this question, we collected intestinal biopsies of healthy controls (n = 34), PSC (n = 25), PSC-IBD (n = 41), and IBD (n = 51) patients in a cross-sectional study and carried out cytokine expression profiling, 16S sequencing, in-depth histology, and endoscopy scoring.RESULTS: We found that the vast majority of PSC patients even without clinically manifest IBD showed infiltration of immune cells and increased expression of IL17A and IFNG in intestinal biopsies. However, expression of IL10 and FOXP3 were likewise increased, which may explain why these PSC patients have intestinal inflammation only on a molecular level. This subclinical inflammation in PSC patients was focused in the distal colon, whereas PSC-IBD patients showed inflammation either at the distal colon or on the right side of the colon and the terminal ileum. Furthermore, we observed that PSC patients without IBD showed signs of dysbiosis and exhibited a distinct microbial profile compared with healthy controls.CONCLUSIONS: We found a gradient of intestinal inflammation in the vast majority of PSC patients even in the absence of IBD. Thus, further studies evaluating the effect of anti-inflammatory therapies in PSC patients and their impact on the emergence of clinically manifest IBD and colorectal cancer development are needed.

AB - BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive liver disease associated with inflammatory bowel disease (IBD). The percentage of PSC patients diagnosed with concomitant IBD varies considerably between studies. This raises the question whether all PSC patients would show intestinal inflammation if screened thoroughly, even in the absence of symptoms.METHODS: To address this question, we collected intestinal biopsies of healthy controls (n = 34), PSC (n = 25), PSC-IBD (n = 41), and IBD (n = 51) patients in a cross-sectional study and carried out cytokine expression profiling, 16S sequencing, in-depth histology, and endoscopy scoring.RESULTS: We found that the vast majority of PSC patients even without clinically manifest IBD showed infiltration of immune cells and increased expression of IL17A and IFNG in intestinal biopsies. However, expression of IL10 and FOXP3 were likewise increased, which may explain why these PSC patients have intestinal inflammation only on a molecular level. This subclinical inflammation in PSC patients was focused in the distal colon, whereas PSC-IBD patients showed inflammation either at the distal colon or on the right side of the colon and the terminal ileum. Furthermore, we observed that PSC patients without IBD showed signs of dysbiosis and exhibited a distinct microbial profile compared with healthy controls.CONCLUSIONS: We found a gradient of intestinal inflammation in the vast majority of PSC patients even in the absence of IBD. Thus, further studies evaluating the effect of anti-inflammatory therapies in PSC patients and their impact on the emergence of clinically manifest IBD and colorectal cancer development are needed.

U2 - 10.1093/ibd/izad137

DO - 10.1093/ibd/izad137

M3 - SCORING: Journal article

C2 - 37540889

VL - 30

SP - 900

EP - 910

JO - INFLAMM BOWEL DIS

JF - INFLAMM BOWEL DIS

SN - 1078-0998

IS - 6

ER -